Novo Nordisk has almost doubled the scale of an R&D alliance with Valo Health – a specialist in applying artificial ...
Novo Nordisk shares fell nearly 30% in the fourth quarter on disappointing clinical trial data, and other concerns. Bank of ...
58m
Aspect Biosystems secures $115M Series B to advance bioprinted tissue therapeutics, accelerating development of functional ...
Under the expanded collaboration, Valo's Opal Computational Platform will be integrated with Novo Nordisk's expertise in cardiometabolic diseases, deriving insights from real-world patient data, ...
Novo Nordisk expanded a deal with Valo Health to discover and develop treatments for obesity, type 2 diabetes and cardiovascular disease using human data and artificial intelligence. The deal extends ...
Drugs for metabolic diseases, vaccines and cancer therapies feature among new product launches this year that could top $1 ...
At least four analysts weighed in on the prospects for Europe’s second-largest company, Novo Nordisk, after the Danish ...
Novo Nordisk is doubling down on its collaboration with Valo Health, committing up to $190 million in near-term payments—and ...
SOUTH SAN FRANCISCO, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company”) announced today that its SomaScan™ Platform played a pivotal role in a study ...
Investing.com - Novo Nordisk (CSE: NOVOb ) remains the "most exciting growth story" in the European pharmaceutical sector and ...
Novo Nordisk (NVO) and Valo Health expand collaboration to develop new treatments targeting cardiometabolic diseases. Read ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback